

Tatsuya Kanto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9479586/publications.pdf>

Version: 2024-02-01

150
papers

5,935
citations

66234

42
h-index

88477

70
g-index

152
all docs

152
docs citations

152
times ranked

8465
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. <i>Journal of Gastroenterology</i> , 2022, 57, 120-132.	2.3	20
2	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis. <i>Hepatology Research</i> , 2022, 52, 665-676.	1.8	4
3	Safety, tolerability, and anti-fibrotic efficacy of the CBP/ β -catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. <i>EBioMedicine</i> , 2022, 80, 104069.	2.7	16
4	Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. <i>Journal of Gastroenterology</i> , 2021, 56, 67-77.	2.3	34
5	Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. <i>Gene</i> , 2021, 766, 145145.	1.0	68
6	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	1.0	28
7	The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 158-167.	2.3	33
8	Nationwide awareness-raising program for viral hepatitis in Japan: the "Shitte kan-en" project. <i>Global Health & Medicine</i> , 2021, 3, 301-307.	0.6	3
9	Increased Frequency of Dysfunctional Siglec-7 ^{hi} CD57 ⁺ PD-1 ⁺ Natural Killer Cells in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2021, 12, 603133.	2.2	13
10	Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. <i>Journal of Gastroenterology</i> , 2021, 56, 470-478.	2.3	25
11	Cluster of Differentiation 44 Promotes Liver Fibrosis and Serves as a Biomarker in Congestive Hepatopathy. <i>Hepatology Communications</i> , 2021, 5, 1437-1447.	2.0	16
12	Myostatin as a fibroblast-activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 803-812.	1.8	18
13	Hepatitis C virus modulates signal peptide peptidase to alter host protein processing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	6
14	Effects of a low-intensity resistance exercise program on serum miR-630, miR-5703, and Fractalkine/CX3CL1 expressions in subjects with No exercise habits: A preliminary study. <i>Hepatology Research</i> , 2021, 51, 823-833.	1.8	11
15	Phenotypic Characterization by Single-Cell Mass Cytometry of Human Intrahepatic and Peripheral NK Cells in Patients with Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1495.	1.8	7
16	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. <i>Immunological Medicine</i> , 2021, 44, 175-186.	1.4	5
17	Prolonged Gut Dysbiosis and Fecal Excretion of Hepatitis A Virus in Patients Infected with Human Immunodeficiency Virus. <i>Viruses</i> , 2021, 13, 2101.	1.5	8
18	Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020, 50, 466-477.	1.8	7

#	ARTICLE	IF	CITATIONS
19	Nationwide survey on activities of regional core centers for the management of liver disease in Japan: Cumulative analyses by the Hepatitis Information Center 2009–2017. <i>Hepatology Research</i> , 2020, 50, 165-173.	1.8	11
20	Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. <i>Journal of Gastroenterology</i> , 2020, 55, 353-362.	2.3	65
21	De novo hepatocellular carcinoma in living donor liver grafts: A Japanese multicenter experience. <i>Hepatology Research</i> , 2020, 50, 1365-1374.	1.8	1
22	Negative immune regulator LNK/SH2B3 contributes to the development of autoimmune liver disease in mice under fatty-metabolic stress. <i>Journal of Hepatology</i> , 2020, 73, S198-S199.	1.8	0
23	Impact of hepatitis B virus-related immune reconstitution inflammatory syndrome on HBsAg loss in patients co-infected with human immunodeficiency virus. <i>Journal of Hepatology</i> , 2020, 73, S597-S598.	1.8	0
24	Tailored message interventions promote the number of participants in viral hepatitis screening for Japanese workers - multicenter trial of 1,127,596 general checkup applicants. <i>Journal of Hepatology</i> , 2020, 73, S800-S801.	1.8	0
25	Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. <i>JHEP Reports</i> , 2020, 2, 100138.	2.6	10
26	A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1388-1398.	1.3	14
27	Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/ β -catenin inhibitor-treated livers. <i>Oncotarget</i> , 2019, 10, 3013-3026.	0.8	13
28	PS-029-Eradication of HCV by DAAs provides patients with immunological benefits by the restoration of antigen-presenting dendritic cells. <i>Journal of Hepatology</i> , 2019, 70, e21-e22.	1.8	0
29	Liver disease secondary to congenital heart disease in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 651-666.	1.4	22
30	Immune Determinants in the Acquisition and Maintenance of Antibody to Hepatitis B Surface Antigen in Adults After First-Time Hepatitis B Vaccination. <i>Hepatology Communications</i> , 2019, 3, 812-824.	2.0	8
31	High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 1046-1053.	1.8	21
32	Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2019, 54, 1007-1018.	2.3	29
33	Efficient and practical dissemination of information on viral hepatitis in Japan: an effort by the Hepatitis Information Center, National Center for Global Health and Medicine. <i>Global Health & Medicine</i> , 2019, 1, 20-22.	0.6	2
34	Hepatocellular carcinoma with non-B and non-C hepatitis origin: epidemiology in Japan and surgical outcome. <i>Global Health & Medicine</i> , 2019, 1, 23-29.	0.6	2
35	Tumor necrosis factor- α -mediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice. <i>Hepatology Communications</i> , 2018, 2, 407-420.	2.0	27
36	Enhanced B-cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1667-1676.	1.4	16

#	ARTICLE	IF	CITATIONS
37	MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. <i>Hepatology Research</i> , 2018, 48, 313-321.	1.8	25
38	Infection with flaviviruses requires BCLXL for cell survival. <i>PLoS Pathogens</i> , 2018, 14, e1007299.	2.1	28
39	Double-Stranded RNA Derived from Lactic Acid Bacteria Augments Th1 Immunity via Interferon- β from Human Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 27.	2.2	22
40	Current activities and future directions of comprehensive hepatitis control measures in Japan: The supportive role of the Hepatitis Information Center in building a solid foundation. <i>Hepatology Research</i> , 2017, 47, 487-496.	1.8	45
41	Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/ β -Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial. <i>EBioMedicine</i> , 2017, 23, 79-87.	2.7	76
42	Pro-angiogenic TIE2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2017, 141, 1011-1017.	2.3	5
43	Hepatitis Action Plan and Changing Trend of Liver Disease in Japan: Viral Hepatitis and Nonalcoholic Fatty Liver Disease. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2017, 7, 60-64.	0.1	8
44	Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. <i>Cytokine</i> , 2016, 88, 29-36.	1.4	2
45	Long noncoding RNA #32 contributes to antiviral responses by controlling interferon-stimulated gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10388-10393.	3.3	76
46	Dual blockade of hepatitis C virus entry at a gatekeeper of hepatocytes: Not only a preventive, but also therapeutic target of claudin 1. <i>Hepatology</i> , 2016, 64, 979-982.	3.6	0
47	Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx. <i>Journal of Virology</i> , 2016, 90, 3530-3542.	1.5	27
48	Indoleamine 2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. <i>Hepatology</i> , 2016, 63, 83-94.	3.6	38
49	Host-virus interactions in hepatitis B and hepatitis C infection. <i>Journal of Gastroenterology</i> , 2016, 51, 409-420.	2.3	23
50	The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. <i>Journal of Gastroenterology</i> , 2016, 51, 370-379.	2.3	41
51	Appropriate use of virtual touch quantification and FibroScan [®] M and XL probes according to the skin capsular distance. <i>Journal of Gastroenterology</i> , 2016, 51, 496-505.	2.3	22
52	Association of serum IFN- γ 3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2015, 50, 894-902.	2.3	30
53	Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients. <i>Journal of Medical Virology</i> , 2014, 86, 241-247.	2.5	13
54	Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1. <i>Journal of Gastroenterology</i> , 2014, 49, 737-747.	2.3	3

#	ARTICLE	IF	CITATIONS
55	Regulation of energy-related ubiquitin E3 ligase, GRAL1, in murine models of colitis and patients with Crohn's disease. <i>Journal of Gastroenterology</i> , 2014, 49, 1524-1535.	2.3	9
56	High-throughput and sensitive next-generation droplet digital PCR assay for the quantitation of the hepatitis C virus mutation at core amino acid 70. <i>Journal of Virological Methods</i> , 2014, 207, 169-177.	1.0	23
57	Liver stiffness measurement by acoustic radiation force impulse is useful in predicting the presence of esophageal varices or high-risk esophageal varices among patients with HCV-related cirrhosis. <i>Journal of Gastroenterology</i> , 2014, 49, 1175-1182.	2.3	48
58	Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. <i>Journal of Gastroenterology</i> , 2013, 48, 660-670.	2.3	41
59	Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. <i>Journal of Gastroenterology</i> , 2013, 48, 535-543.	2.3	2
60	TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. <i>Hepatology</i> , 2013, 57, 1416-1425.	3.6	115
61	The combination therapy of Î±-galactosylceramide and 5-fluorouracil showed antitumor effect synergistically against liver tumor in mice. <i>International Journal of Cancer</i> , 2013, 133, 1126-1134.	2.3	11
62	Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic. <i>Hepatology Research</i> , 2013, 43, 339-346.	1.8	9
63	Valine, the branched-chain amino acid, suppresses hepatitis C virus RNA replication but promotes infectious particle formation. <i>Biochemical and Biophysical Research Communications</i> , 2013, 437, 127-133.	1.0	8
64	The Bcl-2 Homology Domain 3 (BH3)-only Proteins Bim and Bid Are Functionally Active and Restrained by Anti-apoptotic Bcl-2 Family Proteins in Healthy Liver*. <i>Journal of Biological Chemistry</i> , 2013, 288, 30009-30018.	1.6	14
65	Human blood dendritic cell antigen 3 (BDCA3) ⁺ dendritic cells are a potent producer of interferon-Î² in response to hepatitis C virus. <i>Hepatology</i> , 2013, 57, 1705-1715.	3.6	86
66	Interleukin-1Î² enhances the production of soluble MICA in human hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1425-1432.	2.0	17
67	Pancreatic STAT3 Protects Mice against Caerulein-Induced Pancreatitis via PAP1 Induction. <i>American Journal of Pathology</i> , 2012, 181, 2105-2113.	1.9	30
68	Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 167-175.	1.8	313
69	Bak deficiency inhibits liver carcinogenesis: A causal link between apoptosis and carcinogenesis. <i>Journal of Hepatology</i> , 2012, 57, 92-100.	1.8	54
70	Deficiency of N-acetylgalactosamine in O-linked oligosaccharides of IgA is a novel biologic marker for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1723-1734.	0.9	22
71	Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 131, 548-557.	2.3	230
72	Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: A crucial role of CD25 ⁺ FOXP3 ⁺ T cells. <i>International Journal of Cancer</i> , 2012, 131, 2573-2583.	2.3	20

#	ARTICLE	IF	CITATIONS
73	Suppression of signal transducers and activators of transcription 1 in hepatocellular carcinoma is associated with tumor progression. <i>International Journal of Cancer</i> , 2012, 131, 2774-2784.	2.3	20
74	Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin. <i>Journal of Gastroenterology</i> , 2012, 47, 334-342.	2.3	2
75	Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2012, 47, 577-585.	2.3	58
76	Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. <i>Journal of Gastroenterology</i> , 2012, 47, 540-552.	2.3	30
77	Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells. <i>International Journal of Cancer</i> , 2012, 130, 356-364.	2.3	25
78	Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-1 and ribavirin therapy for chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2012, 47, 169-178.	2.3	9
79	Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 614-620.	1.0	15
80	Alterations in microRNA expression profile in HCV-infected hepatoma cells: Involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. <i>Biochemical and Biophysical Research Communications</i> , 2011, 412, 92-97.	1.0	88
81	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. <i>Journal of Hepatology</i> , 2011, 54, 604-611.	1.8	45
82	Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-1 and ribavirin combination therapy in patients with chronic hepatitis C virus infection. <i>Hepatology Research</i> , 2011, 41, 30-38.	1.8	13
83	1-Galactosylceramide activates antitumor immunity against liver tumor. <i>Hepatology Research</i> , 2011, 41, 160-169.	1.8	3
84	Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. <i>Nutrition</i> , 2011, 27, 1023-1028.	1.1	62
85	Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. <i>Journal of Gastroenterology</i> , 2011, 46, 724-35.	2.3	55
86	The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. <i>Journal of Gastroenterology</i> , 2011, 46, 944-952.	2.3	18
87	Differential alteration of CD56bright and CD56dim natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2011, 46, 1020-1030.	2.3	9
88	Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. <i>Journal of Gastroenterology</i> , 2011, 46, 1031-1037.	2.3	13
89	Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study. <i>Journal of Gastroenterology</i> , 2011, 46, 1335-1343.	2.3	9
90	Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1565-1575.	2.0	36

#	ARTICLE	IF	CITATIONS
91	Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. <i>Journal of Medical Virology</i> , 2011, 83, 419-427.	2.5	5
92	Delayed-onset caspase-dependent massive hepatocyte apoptosis upon fas activation in bak/bax-deficient mice. <i>Hepatology</i> , 2011, 54, 240-251.	3.6	26
93	Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 927-936.	0.9	25
94	BH3-only Activator Proteins Bid and Bim Are Dispensable for Bak/Bax-dependent Thrombocyte Apoptosis Induced by Bcl-xL Deficiency. <i>Journal of Biological Chemistry</i> , 2011, 286, 13905-13913.	1.6	78
95	Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 3343-3356.	3.9	138
96	Natural killer cell is a major producer of interferon \hat{I}^3 that is critical for the IL-12-induced anti-tumor effect in mice. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 453-463.	2.0	27
97	EphA2-derived peptide vaccine with amphiphilic poly(\hat{I}^3 -glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 759-767.	2.0	49
98	STAT3 signaling within hepatocytes is required for anemia of inflammation in vivo. <i>Journal of Gastroenterology</i> , 2010, 45, 244-248.	2.3	37
99	Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet. <i>Journal of Gastroenterology</i> , 2010, 45, 1247-1254.	2.3	35
100	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. <i>Hepatology</i> , 2010, 52, 1310-1321.	3.6	126
101	Altered interferon- \hat{I}^1 -signaling in natural killer cells from patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2010, 53, 424-430.	1.8	65
102	Anticancer Chemotherapy Inhibits MHC Class I-Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2009, 69, 8050-8057.	0.4	82
103	Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. <i>Hepatology</i> , 2009, 50, 1217-1226.	3.6	106
104	BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. <i>Hepatology</i> , 2009, 50, 1972-1980.	3.6	23
105	Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2009, 44, 601-607.	2.3	11
106	Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. <i>Journal of Gastroenterology</i> , 2009, 44, 864-870.	2.3	11
107	Effect of interferon \hat{I}^2 plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. <i>Hepatology Research</i> , 2009, 39, 432-438.	1.8	28
108	Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir. <i>Antiviral Therapy</i> , 2009, 14, 873-877.	0.6	9

#	ARTICLE	IF	CITATIONS
109	Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene. <i>Journal of Medical Virology</i> , 2008, 80, 980-988.	2.5	60
110	Serum levels of soluble major histocompatibility complex (MHC) class II-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. <i>Cancer Science</i> , 2008, 99, 1643-1649.	1.7	55
111	Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine. <i>Hepatology Research</i> , 2008, 38, 450-456.	1.8	9
112	Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection. <i>Hepatology Research</i> , 2008, 38, 622-628.	1.8	3
113	A New Prognostic System for Hepatocellular Carcinoma Including Recurrent Cases. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 317-322.	1.1	15
114	Hepatitis C Virus Nonstructural Protein 5A Modulates the Toll-Like Receptor-MyD88-Dependent Signaling Pathway in Macrophage Cell Lines. <i>Journal of Virology</i> , 2007, 81, 8953-8966.	1.5	151
115	Replication-Competent Recombinant Vesicular Stomatitis Virus Encoding Hepatitis C Virus Envelope Proteins. <i>Journal of Virology</i> , 2007, 81, 8601-8612.	1.5	77
116	Type B Fulminant Hepatitis Is Closely Associated with a Highly Mutated Hepatitis B Virus Strain. <i>Intervirology</i> , 2007, 50, 394-401.	1.2	13
117	Natural killer cell-mediated ablation of metastatic liver tumors by hydrodynamic injection of IFN- γ gene to mice. <i>International Journal of Cancer</i> , 2007, 120, 1252-1260.	2.3	24
118	Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon- α and ribavirin therapy for chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2007, 79, 511-521.	2.5	13
119	Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4+ α CD25+T cells with PD-1-dependent regulatory activities. <i>Immunology</i> , 2007, 120, 73-82.	2.0	69
120	Suppressive effect on hepatocyte differentiation of hepatitis C virus core protein. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 1125-1130.	1.0	11
121	Enhanced ability of peripheral invariant natural killer T cells to produce IL-13 in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2006, 45, 190-196.	1.8	27
122	Immunopathogenesis of Hepatitis C Virus Infection: Multifaceted Strategies Subverting Innate and Adaptive Immunity. <i>Internal Medicine</i> , 2006, 45, 183-191.	0.3	71
123	Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection. <i>Hepatology Research</i> , 2006, 34, 156-162.	1.8	30
124	Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?. <i>Hepatology Research</i> , 2006, 35, 185-9.	1.8	36
125	Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2006, 41, 862-872.	2.3	22
126	Impaired Function of Dendritic Cells Circulating in Patients Infected with Hepatitis C Virus Who Have Persistently Normal Alanine Aminotransferase Levels. <i>Intervirology</i> , 2006, 49, 58-63.	1.2	47

#	ARTICLE	IF	CITATIONS
127	Juvenile hepatocellular carcinoma with congestive liver cirrhosis. <i>Journal of Gastroenterology</i> , 2005, 40, 204-208.	2.3	19
128	Negative Regulation of NK Cell Activities by Inhibitory Receptor CD94/NKG2A Leads to Altered NK Cell-Induced Modulation of Dendritic Cell Functions in Chronic Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2004, 173, 6072-6081.	0.4	201
129	Immunopathogenesis of type C hepatitis: dendritic cell in HCV infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S84-S87.	1.4	3
130	Measuring immunity in viral hepatitis. <i>Journal of Gastroenterology</i> , 2004, 39, 709-716.	2.3	5
131	Distinct susceptibility of dendritic cell subsets to hepatitis C virus infection: a plausible mechanism of dendritic cell dysfunction. <i>Journal of Gastroenterology</i> , 2004, 39, 811-812.	2.3	7
132	The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan. <i>Hepatology Research</i> , 2004, 29, 142-147.	1.8	9
133	Concanavalin a injection activates intrahepatic innate immune cells to provoke an antitumor effect in murine liver. <i>Hepatology</i> , 2004, 40, 1190-1196.	3.6	61
134	Involvement of p38 signaling pathway in interferon- γ -mediated antiviral activity toward hepatitis C virus. <i>Biochemical and Biophysical Research Communications</i> , 2004, 321, 722-727.	1.0	35
135	Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. <i>International Journal of Cancer</i> , 2003, 104, 354-361.	2.3	227
136	CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. <i>International Journal of Cancer</i> , 2003, 106, 81-89.	2.3	69
137	Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 32-40.	1.4	31
138	C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. <i>Prostate</i> , 2003, 57, 66-79.	1.2	51
139	Critical Role of MHC Class I-Related Chain A and B Expression on IFN- γ -Stimulated Dendritic Cells in NK Cell Activation: Impairment in Chronic Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2003, 170, 1249-1256.	0.4	242
140	Autocrine/Paracrine IL-15 That Is Required for Type I IFN-Mediated Dendritic Cell Expression of MHC Class I-Related Chain A and B Is Impaired in Hepatitis C Virus Infection. <i>Journal of Immunology</i> , 2003, 171, 5423-5429.	0.4	154
141	A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. <i>Journal of Immunological Methods</i> , 2002, 262, 145-157.	0.6	128
142	Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 309-316.	1.4	14
143	Ceramide Mediates Tumor-Induced Dendritic Cell Apoptosis. <i>Journal of Immunology</i> , 2001, 167, 3773-3784.	0.4	91
144	B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma. <i>Hepatology</i> , 1999, 30, 422-429.	3.6	33

#	ARTICLE	IF	CITATIONS
145	Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. <i>Hepatology</i> , 1998, 27, 240-244.	3.6	148
146	Delayed fas-mediated hepatocyte apoptosis during liver regeneration in mice: hepatoprotective role of TNF?. <i>Hepatology</i> , 1998, 27, 1643-1651.	3.6	55
147	Neutralization of transforming growth factor beta 1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro. <i>Journal of Clinical Immunology</i> , 1997, 17, 462-471.	2.0	22
148	Low expression of erythrocyte complement receptor type 1 in chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 1996, 50, 126-134.	2.5	16
149	Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon- α . <i>Journal of Medical Virology</i> , 1995, 46, 230-237.	2.5	17
150	Density analysis of hepatitis C virus particle population in the circulation of infected hosts: implications for virus neutralization or persistence. <i>Journal of Hepatology</i> , 1995, 22, 440-448.	1.8	73